PRIVA-MOXIFLOXACIN TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)

Verfügbar ab:

PHARMAPAR INC

ATC-Code:

J01MA14

INN (Internationale Bezeichnung):

MOXIFLOXACIN

Dosierung:

400MG

Darreichungsform:

TABLET

Zusammensetzung:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100

Verschreibungstyp:

Prescription

Therapiebereich:

QUINOLONES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0142242001; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2019-08-29

Fachinformation

_Priva-MOXIFLOXACIN _
_ _
_Page 1 of 60 _
PRODUCT MONOGRAPH
PR PRIVA-MOXIFLOXACIN
Moxifloxacin Tablets
(as moxifloxacin hydrochloride)
400 mg
Antibacterial Agent
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
October 16, 2015
Mont-Royal
Qc, H4T 1E2
CONTROL #: 187798
_Priva-MOXIFLOXACIN _
_ _
_Page 2 of 60 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
12
DRUG INTERACTIONS
............................................................................................................................
15
DOSAGE AND ADMINISTRATION
........................................................................................................
17
OVERDOSAGE
..........................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
19
STORAGE AND STABILITY
....................................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............